Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 96-104

  Baltch, A L ^a   Smith, R P ^a   Franke, M A ^a   Ritz, W J ^a   Michelsen, P B ^a   Bopp, L H ^a  

^a STRATTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; NITRIC OXIDE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD LEVEL; CANDIDA ALBICANS; CELL INTERACTION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; MICROBIAL GROWTH; MONOCYTE; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; COLONY-FORMING UNITS ASSAY; CYTOKINES; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MONOCYTES; NITRIC OXIDE; SUPEROXIDES;

EID: 0035160801     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.96-104.2001     Document Type: Article

References (63)

1. Immunodulation in the treatment of invasive fungal infections: Present and future directions
2. Current and future antifungal therapy: New targets for antifungal agents
3. GM-CSF after allogeneic bone marrow transplantation: Accelerated recovery of neutrophils, monocytes and lymphocytes
4. Tumor necrosis factor (TNF) induction from monocyte/macrophages by Candida species
5. National nosocomial infections surveillance system. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
6. Different events involved in the induction of macrophage tumor necrosis factor by Candida albicans and lipopolysaccharide
7. What's new in fungal infection in leukemic patients
8. Macrophage interactions with Candida
9. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes
10. Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFNγ)- and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages
11. Granulocyte-macrophage colony-stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocytes and neutrophils in acquired immunodeficiency syndrome
12. Mechanisms of destruction of Aspergillus fumigatus hyphae mediated by human monocytes
13. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study
14. Epidemiology of nosocomial fungal infections
15. Production of tumor necrosis factor-α in granulocytopenic mice with pulmonary candidiasis and its modification with granulocyte colony-stimulating factor
16. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species
17. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants
18. Serum-mediated enhancement of TNF-α release by human monocytes stimulated with the yeast form of Candida albicans
19. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans
20. Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF)
21. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
22. The molecule of the year
23. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice
24. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide
25. Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A
26. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of disseminated candidiasis
27. Tumor necrosis factor has a protective effect in a murine model of systemic candidiasis
28. Nitric oxide: Physiology, pathophysiology, and pharmacology
29. Cytokine regulation of nitric oxide production
30. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophage and synergy with fluconazole
31. Respiratory burst in adherent human neutrophils: Triggering by colony-stimulating factors CSF-GM and CSF-G
32. A comparative review of colony-stimulating factors
33. Use of macrophage colony-stimulating factor in the treatment of fungal infections
34. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer
35. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
36. Interleukin-10: Potential benefits and possible risks in clinical infectious diseases
37. Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes
38. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis
39. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission
40. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader
41. Novel strategies for treating candidiasis
42. Interferon γ and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia
43. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?
44. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia
45. Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus
46. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
47. Treatment of acute myeloid leukemia with cytokines: Effect on duration of neutropenia and response to infections
48. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes
49. Increased sensitivity of Candida albicans cells accumulating 14α-methylated sterols to active oxygen: Possible relevance to in vivo efficacies of azole antifungal agents
50. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans
51. Interleukin-4 and -10 exacerbate candidiasis in mice
52. Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans; enhanced production of IL-6 and tumour necrosis factor-alpha (TNF-α) by MP-F2-stimulated PMNL from HIV-infected subjects
53. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages
54. Production of IL-6 and TNF-α by the macrophage-like cell line RAW 264.7 after treatment with a cell wall extract of Candida albicans
55. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients
56. Nitric oxide enhances resistance of SCID mice to mucosal candidiasis
57. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B
58. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
59. Cytokine involvement in immunomodulatory activity affected by Candida albicans mannan
60. Differential effects of granulocyte/macrophage colony-stimulating factor (GM-CSF) in enhancing macrophage resistance to Legionella pneumophila vs. Candida albicans